292 related articles for article (PubMed ID: 26061542)
1. Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease.
Sakaguchi Y; Iwatani H; Hamano T; Tomida K; Kawabata H; Kusunoki Y; Shimomura A; Matsui I; Hayashi T; Tsubakihara Y; Isaka Y; Rakugi H
Kidney Int; 2015 Oct; 88(4):833-42. PubMed ID: 26061542
[TBL] [Abstract][Full Text] [Related]
2. The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care.
De Nicola L; Minutolo R; Chiodini P; Borrelli S; Zoccali C; Postorino M; Iodice C; Nappi F; Fuiano G; Gallo C; Conte G;
Kidney Int; 2012 Aug; 82(4):482-8. PubMed ID: 22622495
[TBL] [Abstract][Full Text] [Related]
3. Magnesium and Progression of Chronic Kidney Disease: Benefits Beyond Cardiovascular Protection?
Sakaguchi Y; Hamano T; Isaka Y
Adv Chronic Kidney Dis; 2018 May; 25(3):274-280. PubMed ID: 29793667
[TBL] [Abstract][Full Text] [Related]
4. Interankle systolic blood pressure difference and renal outcomes in patients with chronic kidney disease.
Chen SC; Tsai YC; Huang JC; Lee SC; Chang JM; Hwang SJ; Chen HC
Nephrology (Carlton); 2016 May; 21(5):379-86. PubMed ID: 26370877
[TBL] [Abstract][Full Text] [Related]
5. Effects of Magnesium on the Phosphate Toxicity in Chronic Kidney Disease: Time for Intervention Studies.
Sakaguchi Y; Hamano T; Isaka Y
Nutrients; 2017 Feb; 9(2):. PubMed ID: 28178182
[TBL] [Abstract][Full Text] [Related]
6. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
[TBL] [Abstract][Full Text] [Related]
7. No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease.
Mehrotra R; Peralta CA; Chen SC; Li S; Sachs M; Shah A; Norris K; Saab G; Whaley-Connell A; Kestenbaum B; McCullough PA;
Kidney Int; 2013 Nov; 84(5):989-97. PubMed ID: 23615501
[TBL] [Abstract][Full Text] [Related]
8. Change in novel filtration markers and risk of ESRD.
Rebholz CM; Grams ME; Matsushita K; Selvin E; Coresh J
Am J Kidney Dis; 2015 Jul; 66(1):47-54. PubMed ID: 25542414
[TBL] [Abstract][Full Text] [Related]
9. Phosphate binders in moderate chronic kidney disease: where do we stand?
Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
[TBL] [Abstract][Full Text] [Related]
10. Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD).
Smith ER; Lee D; Cai MM; Tomlinson LA; Ford ML; McMahon LP; Holt SG
Nephrol Dial Transplant; 2013 Jun; 28(6):1569-79. PubMed ID: 23328709
[TBL] [Abstract][Full Text] [Related]
11. Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease.
Chue CD; Edwards NC; Davis LJ; Steeds RP; Townend JN; Ferro CJ
Nephrol Dial Transplant; 2011 Aug; 26(8):2576-82. PubMed ID: 21248296
[TBL] [Abstract][Full Text] [Related]
12. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.
Bansal N; Katz R; Dalrymple L; de Boer I; DeFilippi C; Kestenbaum B; Park M; Sarnak M; Seliger S; Shlipak M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):205-14. PubMed ID: 25605700
[TBL] [Abstract][Full Text] [Related]
13. Magnesium Counteracts Vascular Calcification: Passive Interference or Active Modulation?
Ter Braake AD; Shanahan CM; de Baaij JHF
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1431-1445. PubMed ID: 28663256
[TBL] [Abstract][Full Text] [Related]
14. Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with Stage 3 chronic kidney disease.
Perkins RM; Kirchner HL; Hartle JE; Bucaloiu ID
Clin Nephrol; 2013 Oct; 80(4):256-62. PubMed ID: 23993165
[TBL] [Abstract][Full Text] [Related]
15. The effect of magnesium supplementation on vascular calcification in chronic kidney disease-a randomised clinical trial (MAGiCAL-CKD): essential study design and rationale.
Bressendorff I; Hansen D; Schou M; Kragelund C; Brandi L
BMJ Open; 2017 Jun; 7(6):e016795. PubMed ID: 28645983
[TBL] [Abstract][Full Text] [Related]
16. Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study.
Quiñones H; Hamdi T; Sakhaee K; Pasch A; Moe OW; Pak CYC
J Nephrol; 2019 Feb; 32(1):93-100. PubMed ID: 30465137
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease.
Felsenfeld AJ; Levine BS; Rodriguez M
Semin Dial; 2015; 28(6):564-77. PubMed ID: 26303319
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and impact of proximal fixation on acute and chronic renal dysfunction after endovascular aortic aneurysm repair using glomerular filtration rate criteria.
Pisimisis GT; Bechara CF; Barshes NR; Lin PH; Lai WS; Kougias P
Ann Vasc Surg; 2013 Jan; 27(1):16-22. PubMed ID: 23088805
[TBL] [Abstract][Full Text] [Related]
19. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients.
Kanbay M; Yilmaz MI; Apetrii M; Saglam M; Yaman H; Unal HU; Gok M; Caglar K; Oguz Y; Yenicesu M; Cetinkaya H; Eyileten T; Acikel C; Vural A; Covic A
Am J Nephrol; 2012; 36(3):228-37. PubMed ID: 22948239
[TBL] [Abstract][Full Text] [Related]
20. Serum magnesium, mortality and disease progression in chronic kidney disease.
Azem R; Daou R; Bassil E; Anvari EM; Taliercio JJ; Arrigain S; Schold JD; Vachharajani T; Nally J; Na Khoul GN
BMC Nephrol; 2020 Feb; 21(1):49. PubMed ID: 32050924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
